brand logo

Am Fam Physician. 2023;107(1):90-91

Related AFP Community Blog Post: Semaglutide Shortage Highlights Inequities in Diabetic Medication Access

Author disclosure: No relevant financial relationships.

Semaglutide (Wegovy) is a glucagon-like peptide-1 (GLP-1) receptor agonist. It is labeled for use as an adjunct to diet and exercise for chronic weight management in adults classified as obese (body mass index [BMI] of 30 kg per m2 or greater) or overweight (BMI of 27 kg per m2 or greater) in the presence of one weight-related comorbidity. Semaglutide is also available in a lower-dose injectable formulation (Ozempic) and an oral formulation (Rybelsus) for the treatment of type 2 diabetes mellitus.1

DrugDosageDose formCost*
Semaglutide (Wegovy)0.25 mg once weekly for four weeks, then adjust per the following titration schedule:
 Weeks 5 through 8: 0.5 mg once weekly
 Weeks 9 through 12: 1 mg once weekly
 Weeks 13 through 16: 1.7 mg once weekly
 Week 17 and after: 2.4 mg once weekly
Prefilled, single-dose injector pen:
 0.25 mg per 0.5 mL
 0.5 mg per 0.5 mL
 1 mg per 0.5 mL
 1.7 mg per 0.75 mL
 2.4 mg per 0.75 mL
Already a member/subscriber?  Log In


From $165
  • Immediate, unlimited access to all AFP content
  • More than 130 CME credits/year
  • AAFP app access
  • Print delivery available

Issue Access

  • Immediate, unlimited access to this issue's content
  • CME credits
  • AAFP app access
  • Print delivery available
Purchase Access:  Learn More

STEPS new drug reviews cover Safety, Tolerability, Effectiveness, Price, and Simplicity. Each independent review is provided by authors who have no financial association with the drug manufacturer.

This series is coordinated by Allen F. Shaughnessy, PharmD, assistant medical editor.

A collection of STEPS published in AFP is available at

Continue Reading

More in AFP

More in PubMed

Copyright © 2023 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP.  See permissions for copyright questions and/or permission requests.